BACKGROUND: Tumour necrosis factor alpha (TNF-alpha) has an important role in acute glomerular inflammation. Rolipram, a type IV phosphodiesterase inhibitor, has multiple anti-inflammatory effects including inhibition of TNF-alpha synthesis. METHODS: We investigated the effects of rolipram in prevention and delayed treatment of crescentic glomerulonephritis in Wistar Kyoto rats. Glomerulonephritis was induced by injection of nephrotoxic serum. RESULTS: In the preventive study, rolipram (6.25 mg/kg i.p. twice daily) was started 2.5 h before injection of nephrotoxic serum. Rolipram reduced the expression of TNF-alpha in glomeruli and renal tubules and abrogated glomerular injury on day 4 (99.7% reduction in albuminuria and 96.4% reduction in fibrin deposition). In the delayed-treatment experiment, rolipram was started 4 days after injection of nephrotoxic serum. Rolipram reduced renal excretion of TNF-alpha by 63% on day 7. TNF-alpha was not detected in the sera of treated or control rats. Delayed treatment was effective in crescentic glomerulonephritis, as shown by reduction in albuminuria by 38.1%, fibrin deposition by 60.8%, and crescent formation by 67% on day 7. CONCLUSIONS: Rolipram is effective both in prevention and treatment of experimental crescentic glomerulonephritis. This was associated with a reduction of renal production of TNF-alpha. Copyright 2000 S. Karger AG, Basel
BACKGROUND:Tumour necrosis factor alpha (TNF-alpha) has an important role in acute glomerular inflammation. Rolipram, a type IV phosphodiesterase inhibitor, has multiple anti-inflammatory effects including inhibition of TNF-alpha synthesis. METHODS: We investigated the effects of rolipram in prevention and delayed treatment of crescentic glomerulonephritis in Wistar Kyoto rats. Glomerulonephritis was induced by injection of nephrotoxic serum. RESULTS: In the preventive study, rolipram (6.25 mg/kg i.p. twice daily) was started 2.5 h before injection of nephrotoxic serum. Rolipram reduced the expression of TNF-alpha in glomeruli and renal tubules and abrogated glomerular injury on day 4 (99.7% reduction in albuminuria and 96.4% reduction in fibrin deposition). In the delayed-treatment experiment, rolipram was started 4 days after injection of nephrotoxic serum. Rolipram reduced renal excretion of TNF-alpha by 63% on day 7. TNF-alpha was not detected in the sera of treated or control rats. Delayed treatment was effective in crescentic glomerulonephritis, as shown by reduction in albuminuria by 38.1%, fibrin deposition by 60.8%, and crescent formation by 67% on day 7. CONCLUSIONS:Rolipram is effective both in prevention and treatment of experimental crescentic glomerulonephritis. This was associated with a reduction of renal production of TNF-alpha. Copyright 2000 S. Karger AG, Basel
Authors: Zhijie Xiao; Liqun He; Minoru Takemoto; Hannu Jalanko; Guy C Chan; Daniel R Storm; Christer Betsholtz; Karl Tryggvason; Jaakko Patrakka Journal: Nephron Exp Nephrol Date: 2010-12-24
Authors: Alaa S Awad; Michael Rouse; Lixia Liu; Amy L Vergis; Diane L Rosin; Joel Linden; John R Sedor; Mark D Okusa Journal: J Am Soc Nephrol Date: 2007-11-28 Impact factor: 10.121
Authors: Tabitha Turner-Stokes; Ana Garcia Diaz; Damilola Pinheiro; Maria Prendecki; Stephen P McAdoo; Candice Roufosse; H Terence Cook; Charles D Pusey; Kevin J Woollard Journal: J Am Soc Nephrol Date: 2020-08-31 Impact factor: 10.121
Authors: Jennifer Smith; John P McDaid; Gurjeet Bhangal; Ratana Chawanasuntorapoj; Esteban S Masuda; H Terence Cook; Charles D Pusey; Frederick W K Tam Journal: J Am Soc Nephrol Date: 2009-12-03 Impact factor: 10.121